多omics整合揭示了关键miRNAs,免疫炎症和阿尔茨海默病的信号通路:针对性治疗的含义
Guodong Wang1, Jiawen Duan1, Longfei Sun1
1Guangxi Zhuang Autonomous Region Engineering Research Center for 3D Printing in Smart Biomanufacturing and Application, Guangxi Academy of Medical Sciences, Nanning, 530021, China.
International journal of biological macromolecules
|September 26, 2025
概括
这项研究揭示了突触功能障碍和神经炎症如何驱动阿尔茨海默病 (AD). 研究结果表明,结合免疫调节和神经再生策略可能为AD提供新的治疗途径.
科学领域:
- 神经科学是一个神经科学.
- 基因组学就是基因组学.
- 免疫学 免疫学 免疫学
背景情况:
- 阿尔茨海默病 (AD) 病原体涉及复杂的分子机制,缺乏有效的治疗点.
- 了解突触功能,神经炎症和AD进展之间的相互作用至关重要.
研究的目的:
- 通过多奥米克分析,阐明阿尔茨海默病背后的分子机制.
- 通过整合基因组和转录基因组数据来确定新的治疗点.
- 探索结合免疫调节和神经再生的潜在治疗框架.
主要方法:
- 多omics分析整合miRNA-seq,血液RNA-seq和外周血液单细胞转录组.
- 识别与AD途径相关的差异表达的miRNA和mRNA.
- 候选miRNAs的实验验证及其对神经元分化的影响.
主要成果:
- 确定了与突触功能和免疫反应相关的四个关键miRNA (miR-339-3p,miR-28-3p,miR-423-3p,miR-144-5p).
- 确定了与AD,免疫和亡途径相关的725个mRNA.
- 在阿尔茨海默病患者中,免疫细胞比例的变化表明系统性免疫失调.
- 通过整合omics数据,在JAK-STAT,PI3K-Akt和MAPK通路中确定了388个关键基因.
- 候选miRNAs降低了AD标记物,并促进了神经元前代细胞,表明神经元诱导的潜力.
结论:
- 阿尔茨海默氏病的进展的特点是突触功能障碍和神经炎症的双重作用.
- 这项研究为AD的分子网络提供了新的见解.
- 为AD治疗提出了一种结合免疫调节和神经再生的潜在治疗框架.
更多相关视频
相关概念视频
MicroRNAs
3.8K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.8K
MicroRNAs
23.9K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
23.9K
Alzheimer's Disease: Treatment
824
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
824
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K


